Get started

Financials · PTCT

PTC Therapeutics Inc. (PTCT) financials

For the twelve months ended Sep 30, 2026, PTC Therapeutics Inc. reported $1.16B of revenue and -$105.97M of net income.

Revenue, TTM
$1.16B
Revenue growth, YoY
-35.1%
Net income, TTM
-$105.97M
Net margin
-9.2%
Free cash flow, TTM
$2.07M
EPS, diluted, TTM
-$1.36
Cash
$508.89M
Total debt
$536.27M
P/S
4.70
Market cap
$5.43B
Annual revenue$1.73B
FY2016FY2025
Annual net income$682.64M
FY2016FY2025
Annual free cash flow$702.34M
FY2016FY2025

PTCT revenue and earnings growth

PTCT revenueQ3 2026$357.81M

Quarter YoY
+69.6%
QoQ
-0.8%
FY YoY
+114.5%
5Y CAGR
+35.4%
10Y CAGR
+47.0%

PTCT revenue was $357.81M in fiscal Q3 2026 (ended Sep 30, 2026), up 69.6% from a year earlier and down 0.8% from the prior quarter. For the full fiscal 2025 it was $1.73B, up 114.5% from fiscal 2024. Compound annual growth was +35.4% over 5 years and +47.0% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

PTCT net incomeQ3 2026-$51.69M

PTCT net income was -$51.69M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $15.90M a year earlier. For the full fiscal 2025 it was $682.64M, compared with -$363.30M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.

PTCT EPSQ3 2026-$0.62

PTCT diluted EPS was -$0.62 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0.20 a year earlier. For the full fiscal 2025 it was $7.78, compared with -$4.73 in fiscal 2024.

PTCT free cash flowQ3 2026-$27.97M

PTCT free cash flow was -$27.97M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$69.82M a year earlier. For the full fiscal 2025 it was $702.34M, compared with -$114.19M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$1.73B$806.78M$937.82M$698.80M$538.59M$380.77M$306.98M$264.73M$194.39M$82.70M
Cost of revenue------$12.13M$12.67M$4.58M$0
Gross profit------$294.85M$252.06M$189.81M$82.70M
Research and development$455.25M$534.48M$666.56M$651.50M$540.68M$477.64M$257.45M$171.98M$117.46M$117.63M
Selling, general and admin$347.14M$300.91M$332.54M$326.00M$285.77M$245.16M$202.54M$153.55M$121.27M$97.13M
Operating income$866.93M-$302.57M-$439.50M-$447.41M-$374.44M-$431.77M-$241.16M-$115.69M-$64.29M-$132.06M
Pre-tax income$696.62M-$363.12M-$696.11M-$587.49M-$518.34M-$402.93M-$239.93M-$128.11M-$77.67M-$141.54M
Income tax$13.97M$176.0K-$69.51M-$28.47M$5.56M$35.23M$11.65M-$29.0K$1.33M$569.0K
Net income$682.64M-$363.30M-$626.60M-$559.02M-$523.90M-$438.16M-$251.58M-$128.08M-$79.00M-$142.11M
EPS, basic$8.58-$4.73-$8.37-$7.79-$7.43-$6.64-$4.27-$2.75-$2.02-$4.17
EPS, diluted$7.78-$4.73-$8.37-$7.79-$7.43-$6.64-$4.27-$2.75-$2.02-$4.17
Diluted shares88.3M76.8M74.8M71.7M70.5M66.0M58.9M46.6M39.2M34.0M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$984.65M$795.32M$610.28M$295.93M$197.22M$216.31M$295.53M$169.50M$111.79M$58.32M
Short-term investments$960.72M$359.99M$282.74M$130.87M$583.66M$894.84M$398.54M$58.09M$79.45M$173.34M
Receivables$181.62M$158.55M$160.82M$155.61M$110.45M$69.93M$55.54M$67.91M$40.39M$24.93M
Inventory$79.65M$23.19M$30.58M$21.81M$15.86M$18.70M$19.29M$16.12M$10.75M$0
Current assets$2.27B$1.37B$1.22B$693.78M$954.37M$1.23B$779.28M$320.86M$249.06M$261.29M
Goodwill$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$0-
Total assets$2.90B$1.71B$1.90B$1.71B$1.94B$2.21B$1.62B$1.12B$391.65M$269.35M
Current liabilities$968.43M$580.98M$603.10M$406.24M$509.35M$277.33M$235.86M$166.80M$82.05M$49.62M
Short-term debt$286.63M---$149.54M-$20.00M$11.67M$0-
Long-term debt-$285.41M$284.21M$571.72M$281.89M$309.14M$293.86M$141.35M$144.97M$98.22M
Total debt-$285.41M$284.21M$571.72M$431.43M$309.14M$313.86M$153.01M$144.97M$98.22M
Total liabilities$3.10B$2.80B$2.71B$2.05B$1.94B$1.73B$1.03B$768.50M$235.22M$149.76M
Shareholders' equity-$205.31M-$1.10B-$818.55M-$347.09M$1.44M$481.98M$594.33M$350.73M$156.44M$119.58M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$711.20M-$107.69M-$158.42M-$356.65M-$251.33M-$194.07M-$98.64M-$27.64M-$10.06M-$103.57M
Capital expenditures$8.86M$6.50M$28.44M$32.02M$28.21M$17.84M$13.76M$7.10M$3.10M$1.78M
Free cash flow$702.34M-$114.19M-$186.86M-$388.67M-$279.55M-$211.91M-$112.40M-$34.74M-$13.16M-$105.34M
Investing cash flow-$861.98M$44.18M-$176.74M$290.18M$219.18M-$561.55M-$387.24M-$42.61M$13.12M$104.48M
Financing cash flow$331.09M$255.87M$646.40M$167.95M$20.88M$668.72M$613.21M$131.57M$44.22M$968.0K
Stock-based compensation$74.55M$74.61M$101.64M$110.33M$103.51M$70.33M$42.13M$33.25M$30.56M$35.01M
Depreciation and amortization$38.81M$75.66M$236.59M$128.84M$64.13M$43.49M$32.18M$26.09M$17.68M$3.29M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY114.5%-14.0%34.2%29.7%41.4%24.0%16.0%36.2%135.0%124.9%
Gross margin------96.0%95.2%97.6%100.0%
Operating margin50.1%-37.5%-46.9%-64.0%-69.5%-113.4%-78.6%-43.7%-33.1%-159.7%
Net margin39.4%-45.0%-66.8%-80.0%-97.3%-115.1%-82.0%-48.4%-40.6%-171.8%
Free cash flow margin40.6%-14.2%-19.9%-55.6%-51.9%-55.7%-36.6%-13.1%-6.8%-127.4%
Return on equity-----36432.6%-90.9%-42.3%-36.5%-50.5%-118.8%
Return on assets23.5%-21.3%-33.1%-32.8%-27.0%-19.8%-15.5%-11.4%-20.2%-52.8%
Current ratio2.352.352.021.711.874.443.301.923.045.27
Debt to equity----300.020.640.530.440.930.82

Source: XBRL data PTC Therapeutics Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PTCT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
PTCT$1.16B-35.1%-$105.97M-9.2%$5.43B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

PTCT FAQ

8 questions
  • What is PTCT revenue?
    PTC Therapeutics Inc. (PTCT) reported $1.16B of revenue for the twelve months ended Sep 30, 2026. That is down 35.1% from the year before. Revenue for fiscal 2025 was $1.73B.
  • Is PTCT profitable?
    No. PTC Therapeutics Inc. reported a net loss of $105.97M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does PTCT have?
    PTC Therapeutics Inc. reported $508.89M in cash and cash equivalents and $536.27M of debt on its most recent balance sheet in SEC filings.
  • How fast is PTCT revenue growing?
    PTC Therapeutics Inc.'s revenue changed +114.5% in fiscal 2025, to $1.73B. Its compound annual growth rate was +35.4% over 5 years and +47.0% over 10 years.
  • What is PTCT free cash flow?
    PTC Therapeutics Inc. generated $2.07M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $10.49M less capital expenditures.
  • What is PTCT earnings per share?
    Diluted earnings per share were -$1.36 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did PTCT last report financial results?
    The latest statements here come from PTC Therapeutics Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
  • Where does this PTCT financial data come from?
    Quantisnow builds these statements from the structured XBRL data PTC Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.